Imatinib-Induced Sweet Syndrome in a Patient With Chronic Myeloid Leukemia
Sanjay J. Ayirookuzhi, MD;
Li Ma, MD;
Priya Ramshesh, MD;
Glenn Mills, MD
Arch Dermatol. 2005;141:368.
Background Imatinib mesylate has become one of the main chemotherapeutic agents currently used to treat patients with chronic myeloid leukemia (CML). Although cutaneous reactions to this drug have been documented before, this is the first time that Sweet syndrome has been reported with its use.
Observations We report a case of Sweet syndrome secondary to the administration of imatinib to treat CML. On 2 separate occasions, a 53-year-old African American woman with CML developed neutrophilic dermatosis consistent with Sweet syndrome after chemotherapy with imatinib.
Conclusion Greater awareness of the adverse effects of imatinib and the characterization of its cutaneous adverse effects will lead to improved surveillance for and treatment of those adverse effects.
Author Affiliations: Departments of Medicine (Dr Ayirookuzhi), Pathology (Dr Ma), and Hematology and Oncology (Drs Ramshesh and Mills), Louisiana State University Health Sciences Center at Shreveport, Shreveport.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Bullous Sweet Syndrome in a Patient With t(9;22)(q34;q11)-Positive Chronic Myeloid Leukemia Treated With the Tyrosine Kinase Inhibitor Nilotinib: Interphase Cytogenetic Detection of BCR-ABL- Positive Lesional Cells
Kaune et al.
Arch Dermatol 2008;144:361-364.
ABSTRACT
| FULL TEXT
Drug-Induced Sweet's Syndrome
Thompson and Montarella
The Annals of Pharmacotherapy 2007;41:802-811.
ABSTRACT
| FULL TEXT
Newly Reported Associations with Neutrophilic Dermatoses
Journal Watch Dermatology 2005;2005:6-6.
FULL TEXT
|
